Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

MRK 57.51 +0.52 (0.91%)
price chart
BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead
Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE). Meanwhile biotech investors ...
Earnings Whispers - Merck & Co., Inc. (MRK) To Report Q2 Earnings Today  Bidness ETC
Merck & Co., Inc. (MRK) Updates FY15 Earnings Guidance  Dakota Financial News
Merck & Company, Inc. (NYSE:MRK) Short Interest Update
Merck & Company, Inc. (NYSE:MRK) stated loss of 3,211,563 shares or 9.8% in the short interest. The short interest registered from 32,685,406 on June 30,2015 to 29,473,843 on July 15,2015.
Merck raises forecast on strong sales of diabetes, cancer drugs  Reuters
Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM ...  MarketWatch
Active Stocks Trader's Buzzers: Merck & Co. Inc. (NYSE:MRK), MetLife, Inc ...
Merck & Co., known as MSD outside the United States and Canada, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the ...
Large Inflow of Money Witnessed in Merck & Company, Inc.
Merck & Company, Inc. (NYSE:MRK) traded with a cut of -0.42 points or -0.73% at $56.99 per share. As per the last available information, the stock aggregated $136.31 million in upticks and $93.64 million in downticks, keeping the net money flow capped ...
Merck & Co., Inc. (MRK) Releases FY15 Earnings Guidance  Mideast Time
Merck & Co. (MRK) Announces Quarterly Earnings Results, Beats Estimates ...  Dakota Financial News
ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO ...
"The expansion of this ongoing collaboration with Ablynx allows us to increase our ability to evaluate the potential of more immune checkpoint targets for the treatment of cancer.
Shares of Merck & Company, Inc. (NYSE:MRK) Sees Large Inflow of Net Money Flow
Merck & Company, Inc. (NYSE:MRK) had a weak trading session and its shares were last down at $57.41, down -0.66% or -1.14 points.
Stock to Follow: Merck & Co Inc (NYSE:MRK)
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for ...
Merck Announces European Medicines Agency Acceptance of Marketing ...  MarketWatch
Strong dollar weighs on Merck & Co revenue, reports 11% drop
Merck & Co Inc reported a nearly 11 per cent drop in quarterly revenue as a strong dollar and the sale of its consumer care business overshadowed strong demand for its diabetes drugs.
Strong dollar weighs on Merck revenue  Vocal Republic
Europe's CHMP backs Merck's ZERBAXA (MRK)
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting approval for Merck's (MRK -1.2%) ZERBAXA (ceftolozane/tazobactam) for the treatment of adult patients with complicated ...
Allergan PLC On A Roll; Buys Merck & Co. Migraine Drug Rights
Allergan PLC (NYSE:AGN) announced on Tuesday it has entered into an agreement with Merck & Co., Inc. (NYSE:MRK), under which it would acquire exclusive global rights to two of Merck's migraine drugs currently in experimental stages, MK-1602 and ...
Merck & Co. Inc. (NYSE:MRK) and Allergan plc (AGN) Signs Into an ...  StreetWise Report
Merck & Co., Inc. (NYSE:MRK) Sells Its Migraine Drugs To Allergan PLC ...  USMarketsDaily (blog)